Treatment
Teplizumab clinical trials
We’re tracking 7 recruiting studies that include Teplizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07088068RecruitingPhase 3
Teplizumab for newly diagnosed type 1 diabetes
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
Scottsdale, ArizonaAges 1–25 - NCT07260110Recruiting
Study of teplizumab vs. no treatment in stage 2 type 1 diabetes
This study watches people with stage 2 type 1 diabetes who either get teplizumab or not, to compare their real-world experiences. It helps researchers learn how the drug affects daily life.
San Francisco, CaliforniaAges 8 years+ - NCT06791291RecruitingPhase 2
Teplizumab for Japanese with early-stage type 1 diabetes
This trial tests an experimental drug called teplizumab to see if it can slow down or stop type 1 diabetes from getting worse. It is for Japanese people aged 1 to 34 who have stage 2 type 1 diabetes (blood sugar is slightly abnormal but not yet full diabetes).
Ichikawa, ChibaAges 1–34 - NCT07360080Recruiting
Long-Term Effects of Teplizumab in Real-World Care
This study follows people who have already received teplizumab (a treatment to delay type 1 diabetes) to see how they do over time. It aims to understand the long-term effects in routine care.
Atlanta, GeorgiaAges Any age - NCT07457580Recruiting
A real-world study of teplizumab for type 1 diabetes
This study looks at real-world outcomes in patients with type 1 diabetes who received teplizumab through managed access programs. It helps researchers understand how well the treatment works outside of a clinical trial setting.
LeuvenAges Any age - NCT06338553RecruitingEarly Phase 1
GLP-1 drug for early type 1 diabetes
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
Nashville, TennesseeAges 12–50 - NCT06481904Recruiting
Registry for stage 2 type 1 diabetes
This study tracks people with stage 2 type 1 diabetes to see how they do over time, either with or without treatment with a drug called TZIELD. It helps doctors learn more about the disease and the effects of this treatment.
Los Angeles, CaliforniaAges Any age
What Teplizumab is being studied for
Conditions with recruiting Teplizumab studies.
Common questions
- Are there clinical trials studying Teplizumab?
- Yes. Clin2 currently lists 7 recruiting studies that include Teplizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Teplizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Teplizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Teplizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.